Evelo Biosciences (EVLO) Stock Price, News & Analysis

Company Overview

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $0.0005 to $0.0005
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.02
• Volume: 246 shs
• Average Volume: 10,555 shs
• Market Capitalization: $9.49 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

EVLO Stock Analysis - Frequently Asked Questions

How have EVLO shares performed this year?

Evelo Biosciences' stock was trading at $0.0005 at the beginning of the year. Since then, EVLO stock has increased by 0.0% and is now trading at $0.0005.

How were Evelo Biosciences' earnings last quarter?

Evelo Biosciences, Inc. (NASDAQ:EVLO) announced its quarterly earnings results on Wednesday, October, 27th. The company reported ($12.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($10.80) by $1.80.

When did Evelo Biosciences' stock split?

Evelo Biosciences shares reverse split on the morning of Friday, June 30th 2023.The 1-20 reverse split was announced on Friday, June 30th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Evelo Biosciences IPO?

Evelo Biosciences (EVLO) raised $85 million in an initial public offering (IPO) on Wednesday, May 9th 2018. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager.

How do I buy shares of Evelo Biosciences?

Shares of EVLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Evelo Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Evelo Biosciences investors own include Sangamo Therapeutics (SGMO), Fulcrum Therapeutics (FULC), CymaBay Therapeutics (CBAY), Provention Bio (PRVB), VIVUS (VVUS), Meta Platforms (META) and Entasis Therapeutics (ETTX).

Company Calendar

• Last Earnings: 10/27/2021
• Today: 8/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EVLO
• CIK: 1694665
• Web: www.evelobio.com
• Phone: (617) 577-0300
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 18,983,000
• Free Float: 18,789,000
• Market Cap: $9.49 thousand
• Optionable: No Data
• Beta: 0.88